Stockreport

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma [Yahoo! Finance]

Dr. Reddy's Laboratories Ltd  (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
PDF ligands, PD-L1 and PD-L2, and for enhanced receptor internalisation (endocytosis function). It is used for the treatment of adults with recurrent or metastatic nasophary [Read more]